Latest Articles
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype - londoninsider.co.uk
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk
Published: July 15, 2026, 11:49 p.m.
Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first - Fierce Pharma
Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first Fierce Pharma
Published: July 15, 2026, 7:33 p.m.
PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer - Medscape Reference
PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer Medscape Reference
Published: June 17, 2026, 2:51 p.m.
Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer - OncLive
Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer OncLive
Published: April 8, 2025, 1:11 p.m.
Future of cancer treatment in PD-1 subcutaneous injections - Medical News Today
Future of cancer treatment in PD-1 subcutaneous injections Medical News Today
Published: April 4, 2025, 5 p.m.
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - BioMed Central
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis BioMed Central
Published: Feb. 28, 2025, 10:47 a.m.
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - bmcwomenshealth.biomedcentral.com
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis bmcwomenshealth.biomedcentral.com
Published: Feb. 28, 2025, 10:47 a.m.
Link copied to clipboard!